A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs HMPL 689 (Primary)
- Indications Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 13 Mar 2019 Planned End Date changed from 1 Jan 2020 to 1 Jul 2021.
- 13 Mar 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 31 Aug 2018 Biomarkers information updated